CO2020014430A2 - Inhibidor de la interacción proteína-proteína fenil triazol mll1-wdr5 - Google Patents

Inhibidor de la interacción proteína-proteína fenil triazol mll1-wdr5

Info

Publication number
CO2020014430A2
CO2020014430A2 CONC2020/0014430A CO2020014430A CO2020014430A2 CO 2020014430 A2 CO2020014430 A2 CO 2020014430A2 CO 2020014430 A CO2020014430 A CO 2020014430A CO 2020014430 A2 CO2020014430 A2 CO 2020014430A2
Authority
CO
Colombia
Prior art keywords
protein
mll1
wdr5
interaction
inhibitor
Prior art date
Application number
CONC2020/0014430A
Other languages
English (en)
Inventor
Qidong You
Xiaoke Guo
Dongdong Li
Weilin Chen
Zhihui Wang
Original Assignee
Univ China Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ China Pharma filed Critical Univ China Pharma
Publication of CO2020014430A2 publication Critical patent/CO2020014430A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al campo de la química médica, en particular a un inhibidor de la interacción proteína-proteína (I) de fenil triazol MLL1-WDR5 y un método de preparación del mismo, y los experimentos de farmacodinamia demuestran que el compuesto de la invención tiene una proteína MLL1-WDR5 relativamente fuerte. -actividad de inhibición de la interacción de proteínas.
CONC2020/0014430A 2018-04-23 2020-11-20 Inhibidor de la interacción proteína-proteína fenil triazol mll1-wdr5 CO2020014430A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810365880.0A CN108715585A (zh) 2018-04-23 2018-04-23 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
PCT/CN2018/123500 WO2019205687A1 (zh) 2018-04-23 2018-12-25 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂

Publications (1)

Publication Number Publication Date
CO2020014430A2 true CO2020014430A2 (es) 2021-05-20

Family

ID=63899366

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0014430A CO2020014430A2 (es) 2018-04-23 2020-11-20 Inhibidor de la interacción proteína-proteína fenil triazol mll1-wdr5

Country Status (17)

Country Link
US (2) US11479545B2 (es)
EP (1) EP3786157A4 (es)
JP (1) JP7274765B2 (es)
KR (1) KR20210019414A (es)
CN (2) CN108715585A (es)
AU (1) AU2018420231A1 (es)
BR (1) BR112020021569A2 (es)
CA (1) CA3097925A1 (es)
CL (1) CL2020002736A1 (es)
CO (1) CO2020014430A2 (es)
EA (1) EA202092317A1 (es)
IL (1) IL278255B2 (es)
MX (1) MX2020011205A (es)
PH (1) PH12020551756A1 (es)
SG (1) SG11202010492SA (es)
WO (1) WO2019205687A1 (es)
ZA (1) ZA202006581B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3784663T1 (sl) 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
CN108715585A (zh) 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
CN109734674B (zh) * 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
US20230286925A1 (en) * 2022-03-14 2023-09-14 Huyabio International, Llc Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor
WO2023177591A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
WO2024002379A1 (zh) * 2022-07-01 2024-01-04 甘李药业股份有限公司 一种用作wdr5抑制剂的化合物或其可药用盐及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056535A1 (en) * 2003-12-03 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. 1,2,3-triazole amide derivatives as inhibitors of cytokine production
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN104844573A (zh) 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
CN105175284B (zh) * 2015-07-21 2017-06-16 中国药科大学 酰胺类化合物、制备方法及其医药用途
CN109071423A (zh) 2016-02-09 2018-12-21 益方生物科技（上海）有限公司 吲哚胺-2,3-双加氧酶(ido)抑制剂
WO2017147701A1 (en) * 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibitors of wdr5 protein-protein binding
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN108715585A (zh) 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂

Also Published As

Publication number Publication date
IL278255B1 (en) 2023-05-01
CN112368268A (zh) 2021-02-12
EP3786157A1 (en) 2021-03-03
CN108715585A (zh) 2018-10-30
AU2018420231A1 (en) 2020-12-10
US20210139466A1 (en) 2021-05-13
KR20210019414A (ko) 2021-02-22
CA3097925A1 (en) 2019-10-31
EP3786157A4 (en) 2022-01-05
MX2020011205A (es) 2021-02-09
EA202092317A1 (ru) 2021-07-23
BR112020021569A2 (pt) 2021-04-13
JP7274765B2 (ja) 2023-05-17
JP2021525226A (ja) 2021-09-24
PH12020551756A1 (en) 2021-08-16
ZA202006581B (en) 2023-05-31
CL2020002736A1 (es) 2021-05-28
IL278255A (es) 2020-12-31
SG11202010492SA (en) 2020-11-27
IL278255B2 (en) 2023-09-01
US20230098016A1 (en) 2023-03-30
US11479545B2 (en) 2022-10-25
WO2019205687A1 (zh) 2019-10-31

Similar Documents

Publication Publication Date Title
CO2020014430A2 (es) Inhibidor de la interacción proteína-proteína fenil triazol mll1-wdr5
CO2017010583A2 (es) Compuestos de pirazol y método para elaborar y usar los compuestos
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2022006105A2 (es) Compuesto de péptidos cíclicos que tiene acción inhibidora de kras
CL2021001735A1 (es) Inhibidores irreversibles de la interacción menina-mll.
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
UY36014A (es) ?derivado de pirazol amida, composición farmacéutica y método para tratar o prevenir enfermedades autoinmunes, inflamatorias, metabólicas o cancerosas?.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CL2020001624A1 (es) Cocristales de boscalida y triazoles.
EA201892051A1 (ru) Фармацевтические композиции для лечения злокачественного новообразования
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2018008614A (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
EA202092909A1 (ru) Новый бензодиазепин, его производные и применение
CL2019003037A1 (es) Combinaciones fungicidas.
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer